Skip to the main content.
Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

1 min read


South San Francisco, Calif., Nov 13, 2012 -- Fluxion Biosciences, Inc. announced today that it has launched its IsoFlux System for circulating tumor cell (CTC) analysis at the 3rd annual World CTC Summit in Boston. The system is now commercially available and will begin shipping to customers.

The IsoFlux System is a benchtop instrument that utilizes a proprietary microfluidic technology to isolate CTCs and other rare cell types from blood samples. CTCs disseminate from primary tumors and circulate throughout the peripheral blood in concentrations around 1 CTC in a billion blood cells. This falls below the sensitivity limits of convention cell sorting technologies. The IsoFlux System was designed to isolate rare CTCs with high capture efficiency and pass them on to downstream analyses.

"Personalized medicine holds great promise for the clinical management of cancer, yet one of the key issues is reliable access to cellular material for analysis," said Jeff Jensen, CEO. "We believe the launch of the IsoFlux System will help fill this void by offering a 'liquid biopsy' in a format that is compatible with next-generation molecular technologies.

"IsoFlux samples get processed under more controlled and uniform conditions than bulk separations. This contributes to increased cell capture efficiency, purity, and viability. Samples processed with the IsoFlux System are optimized for downstream molecular testing such as real-time PCR, next generation sequencing (NGS), and immunoassays."We've been very pleased with the feedback we've received from our Early Access customers, which have included leading pharma, biotech, and clinical research institutes," said Michael Schwartz, Program Director. "Their validation of the system across many different pathologies and downstream applications has helped paved the way for the commercial launch of the IsoFlux System."

The IsoFlux System is manufactured at Fluxion's South San Francisco headquarters at a facility registered with the FDA for medical device manufacturing. The IsoFlux System is listed as a Class I medical device for In Vitro Diagnostic Use for the dilution of blood samples to enrich for CTCs and prepare them for further analysis.

About Fluxion Biosciences

Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Fluxion's proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Products include the BioFlux(TM) System for studying cellular interactions, the IonFlux(TM) System for high throughput patch clamp measurements, and the IsoFlux(TM) System for circulating tumor cells. Fluxion's systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit


Jeff Jensen
Fluxion Biosciences, Inc.
1 (650) 241-4747